|
gptkbp:instanceOf
|
gptkb:drug
protease inhibitor
|
|
gptkbp:administeredBy
|
gptkb:prednisone
gptkb:dexamethasone
gptkb:melphalan
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX32
|
|
gptkbp:brand
|
gptkb:Velcade
|
|
gptkbp:CASNumber
|
179324-69-7
|
|
gptkbp:category
|
small molecule
antineoplastic agent
orphan drug
|
|
gptkbp:chemicalClass
|
boronic acid derivative
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity to boron
|
|
gptkbp:developedBy
|
gptkb:Millennium_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:Julian_Adams
|
|
gptkbp:discoveredIn
|
1995
|
|
gptkbp:eliminationHalfLife
|
40 hours
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:hasMolecularFormula
|
C19H25BN4O4
|
|
gptkbp:hasSMILES
|
B(C1=CC=CC=C1)(C2=NC(C(C2)NC(=O)C(C(C)C)NC(=O)C(CO)N)=O)O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bortezomib
|
|
gptkbp:KEGGID
|
D03136
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits 26S proteasome
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2017 (US)
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
83%
|
|
gptkbp:PubChem_CID
|
387447
DB00188
342444
CHEMBL325855
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
peripheral neuropathy
thrombocytopenia
gastrointestinal disturbances
|
|
gptkbp:UNII
|
QPL8W5568D
|
|
gptkbp:usedFor
|
gptkb:mantle_cell_lymphoma
multiple myeloma
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Darzalex
gptkb:CYP3A4_gene
|
|
gptkbp:bfsLayer
|
6
|